CClinicalTrials.gg
CompletedNCT00901875Updated Nov 30, 2012

Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan

A Phase 4 interventional study of Buprenorphine + naloxone (Suboxone) and Buprenorphine + naloxone (Suboxone) in Opiate Dependence, sponsored by Indivior Inc.. Completed at 8 sites in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-11-30.

Sponsored by Indivior Inc. · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

To determine whether Suboxone can be effectively used to treat Taiwanese ethnic subjects with opiate dependence.

02

Conditions studied

  • Opiate Dependence

Keywords

  • Buprenorphine
  • Naloxone
  • Suboxone
03

In context

Opioid-Related Disorders

1,411 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.

This study's enrollment of 127 is above the median of 63 across 1,123 interventional studies indexed under Opioid-Related Disorders.

Browse Opioid-Related Disorders studies →

Lead sponsor

Indivior Inc. is the lead sponsor of 51 studies on the registry; none are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male or female subjects, 20 years of age or older at screening visit.
  • Subjects must meet DSM-IV/COWS1,2 criteria for opiate dependence. (COWS total score ≥5)
  • Subjects must have a positive urine drug screen (dipstick test) for an opiate or morphine at study entry
  • Subject is seeking treatment with the desire to discontinue opiate use as an initial goal but willing to consider and accept longer treatment if necessary.
  • Subject is in good physical health or, if he/she has a medical condition needing ongoing treatment, must be in the care of a physician who is willing to take responsibility for such treatment and work with the study physician. Study physicians able to manage the subject for his/her general medical condition, may be assigned this role. These same conditions apply in case of subjects with psychiatric disorder(s) needing ongoing treatment.
  • Subject is agreeable to and capable of signing informed consent form.
  • Females of childbearing potential must have a negative pregnancy test and agree to use a double barrier method or condoms/diaphragm and spermicide contraceptive method during the study.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, lactating or breast feeding.
  • Subjects have any acute medical condition that would make participation, in the opinion of the treating physician or the principal investigator, medically hazardous (e.g., acute hepatitis, unstable cardiovascular, liver or renal disease).
  • Subjects have clinically significant liver disease.
  • Subjects who have demonstrated a previous hypersensitivity to buprenorphine or naloxone.
  • Subjects who are considered an immediate risk for suicide, are acutely psychotic, severely depressed, or in need of inpatient treatment.
  • Subjects who are dependent on alcohol, benzodiazepines or other drugs of abuse (except tobacco) to the point of requiring immediate medical attention.
  • Subjects received methadone treatment within the last 30 days since screening visit.
  • Subjects have any pending legal action that could prohibit continued participation.
  • Subjects have participated in other clinical studies within the past 30 days.
  • Subjects who are expecting to leave the clinic geographic area prior to study completion.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    Suboxone, maximum 8mg

    Drug: Buprenorphine + naloxone (Suboxone)

  • Experimental
    Buprenorphine + naloxone

    Drug: Buprenorphine + naloxone (Suboxone)

  • Experimental
    Buprenorphine + naloxone (Suboxone)

    Drug: Buprenorphine + naloxone (Suboxone)

Interventions

  • DrugBuprenorphine + naloxone (Suboxone)

    Sublingual tablets

    Also known as: Suboxone

  • DrugBuprenorphine + naloxone (Suboxone)

    Also known as: Suboxone

06

What researchers measure

Primary outcomes

  1. Retention in treatment

    Time frame: weekly up to 13 weeks

07

Study locations

8 sites
  • Jianan Mental Hospital
    Ren-De, Tainan County, Taiwan
  • Taoyuan Mental Hospital
    Taoyuan City, Taoyuan County 330, Taiwan
  • Chang-Gung Memorial Hospital, Linkou Branch
    Gueishan, Taiwan
  • Chang-Gung Memorial Hospital, Keelung Branch
    Keelung, 204, Taiwan
  • China Medical University Hospital
    Taichung, 40447, Taiwan
  • Taipei City Hospital - Song De Branch
    Taipei, 110, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 112, Taiwan
  • BALI Psychiatric Center
    Taipei, 24936, Taiwan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00901875
Lead sponsor
Indivior Inc.
Collaborators
Taipei City Psychiatric Center, Taiwan
Responsible party
Sponsor
First posted
May 14, 2009
Start date
Mar 2009
Primary completion
Nov 2009
Completion
Jan 2010
Last update
Nov 30, 2012

Study contacts

Shih-Ku Lin, MD
principal investigator · Department of Psychiatry, Taipei City Psychiatric Center, Taipei, Taiwan.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion